Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
10x Genomics downgraded to Sell from Neutral at Goldman Sachs » 04:37
08/18/22
08/18
04:37
08/18/22
04:37
TXG

10x Genomics

$42.89 /

-3.475 (-7.49%)

Goldman Sachs analyst…

Goldman Sachs analyst Matthew Sykes downgraded 10x Genomics to Sell from Neutral with a price target of $35, down from $55, which represents 18% downside from current levels. The analyst expects a "materially slower cadence" to the company's sales growth rate in 2023 and 2024 versus consensus as it transitions to a multi-market, multi-product company. The growth rate for 10x's single cell analysis business is below what analysts have modeled over the next few years as its penetration into the academic market "has hit a ceiling amongst the high utilization, core lab customers," Sykes tells investors in a research note. He adds that the company's spatial and in situ offerings "are not yet of the size to help offset the deceleration in their core business."

ShowHide Related Items >><<
TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
08/10/22 Morgan Stanley
10x Genomics price target lowered to $70 from $100 at Morgan Stanley
08/09/22 Cowen
10x Genomics price target raised to $55 from $50 at Cowen
08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

TXG 10x Genomics
$42.89 /

-3.475 (-7.49%)

Downgrade
Singular Genomics downgraded to Neutral from Buy at UBS » 05:55
08/17/22
08/17
05:55
08/17/22
05:55
OMIC

Singular Genomics

$4.02 /

-0.29 (-6.73%)

UBS analyst John Sourbeer…

UBS analyst John Sourbeer downgraded Singular Genomics to Neutral from Buy with a price target of $4.50, down from $10, after the company provided a "disappointing" Q2 update. Unexpected delays regarding key electronic components for instruments is leading to delays in shipping G4 units to customers, noted Sourbeer, who is cutting his 2022 and 2023 shipment estimates by 75% and 45%, respectively. While he points to "several impressive features" of the G4 that give it an opportunity to gain share in the short-read NGS market, he now sees a slower ramp over the near-term, Sourbeer added.

ShowHide Related Items >><<
OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

08/17/22 UBS
Singular Genomics downgraded to Neutral from Buy at UBS
08/10/22 BofA
Singular Genomics downgraded to Underperform from Buy at BofA
08/10/22 Goldman Sachs
Singular Genomics downgraded to Neutral from Buy at Goldman Sachs
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

Downgrade
Singular Genomics downgraded to Neutral from Buy at UBS » 05:53
08/17/22
08/17
05:53
08/17/22
05:53
OMIC

Singular Genomics

$4.02 /

-0.29 (-6.73%)

UBS analyst John Sourbeer…

UBS analyst John Sourbeer downgraded Singular Genomics to Neutral from Buy with a price target of $4.50, down from $10.

ShowHide Related Items >><<
OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

08/10/22 BofA
Singular Genomics downgraded to Underperform from Buy at BofA
08/10/22 Goldman Sachs
Singular Genomics downgraded to Neutral from Buy at Goldman Sachs
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

OMIC Singular Genomics
$4.02 /

-0.29 (-6.73%)

Recommendations
Illumina miss 'surprising' given backlog, says Piper Sandler » 16:41
08/11/22
08/11
16:41
08/11/22
16:41
ILMN

Illumina

$227.64 /

+0.44 (+0.19%)

, PACB

Pacific Biosciences

$7.94 /

+0.245 (+3.18%)

, TXG

10x Genomics

$48.22 /

+1.27 (+2.71%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg notes that Illumina just reported revenues, earnings and guidance that came in "well below consensus," which he calls "surprising" given the company's "rich" backlog of NovaSeq instruments and consumables. The analyst, who sees the miss potentially signaling that new orders in excess of backlog filling slowed "dramatically," argues that "the silver lining, if any," is that most of the other single products genomics companies, such as Pacific Biosciences (PACB) and 10x Genomics (TXG), also noted transitory headwinds from the macro environment. Westenberg, who thinks Illumina continues to have a strong competitive position, has an Overweight rating on the shares, which are down $51.49, or 23%, to $175.95 in after-hours trading.

ShowHide Related Items >><<
TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

07/14/22 Canaccord
Illumina merger challenge not reflection of merits, says Canaccord
07/13/22 Piper Sandler
Illumina uncertainty over Grail continues with ruling, says Piper Sandler
07/13/22 Barclays
Illumina downgraded to Underweight from Equal Weight at Barclays
07/08/22 Citi
Illumina price target lowered to $220 from $325 at Citi
PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

08/04/22 Canaccord
Pacific Biosciences price target lowered to $14 from $17 at Canaccord
05/15/22 Piper Sandler
Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler
05/05/22 Cantor Fitzgerald
Pacific Biosciences price target lowered to $19 from $23 at Cantor Fitzgerald
03/01/22 Piper Sandler
Pacific Biosciences price target lowered to $13 from $20 at Piper Sandler
TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

08/10/22 Morgan Stanley
10x Genomics price target lowered to $70 from $100 at Morgan Stanley
08/09/22 Cowen
10x Genomics price target raised to $55 from $50 at Cowen
08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

TXG 10x Genomics
$48.22 /

+1.27 (+2.71%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

PACB Pacific Biosciences
$7.94 /

+0.245 (+3.18%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

Recommendations
10x Genomics price target lowered to $70 from $100 at Morgan Stanley » 08:45
08/10/22
08/10
08:45
08/10/22
08:45
TXG

10x Genomics

$44.88 /

+1.43 (+3.29%)

Morgan Stanley analyst…

Morgan Stanley analyst Tejas Savant lowered the firm's price target on 10x Genomics to $70 from $100 and keeps an Overweight rating on the shares after the company reported Q2 results in line with its preannouncement and cut guidance, which was "unsurprising" following the preliminary release. The meaningful outlook reset should be "a clearing event for the stock," said Savant, who likes the setup into 2023 and beyond with Fixed RNA Profiling and CytAssist seeing strong initial traction and Xenium on track for year-end.

ShowHide Related Items >><<
TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

08/09/22 Cowen
10x Genomics price target raised to $55 from $50 at Cowen
08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

TXG 10x Genomics
$44.88 /

+1.43 (+3.29%)

Downgrade
Singular Genomics downgraded to Underperform from Buy at BofA » 06:04
08/10/22
08/10
06:04
08/10/22
06:04
OMIC

Singular Genomics

$4.44 /

-0.21 (-4.52%)

BofA analyst Michael…

BofA analyst Michael Ryskin downgraded Singular Genomics to Underperform from Buy with a $3 price target.

ShowHide Related Items >><<
OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

08/10/22 Goldman Sachs
Singular Genomics downgraded to Neutral from Buy at Goldman Sachs
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/06/22 UBS
Singular Genomics price target lowered to $25 from $32 at UBS
OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

Downgrade
Singular Genomics downgraded to Neutral from Buy at Goldman Sachs » 04:41
08/10/22
08/10
04:41
08/10/22
04:41
OMIC

Singular Genomics

$4.44 /

-0.21 (-4.52%)

Goldman Sachs analyst…

Goldman Sachs analyst Matthew Sykes downgraded Singular Genomics to Neutral from Buy with a $3.50 price target, presenting 21% downside from current levels. The company has experienced supply chain issues that has caused a shipment delay of three months to its original timeline, Sykes tells investors in a research note. The delays have resulted in a slower cadence of placements, leading the analyst to lower his G4 placement forecast from 34 to four in 2022, 73 to 39 in 2023 and 109 to 70 in 2024. As a result, Sykes currently see better opportunities within his coverage universe.

ShowHide Related Items >><<
OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/06/22 UBS
Singular Genomics price target lowered to $25 from $32 at UBS
10/14/21 Cowen
Singular Genomics coverage transferred at Cowen
OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

Earnings
Singular Genomics reports Q2 EPS (34c), consensus (38c) » 16:18
08/09/22
08/09
16:18
08/09/22
16:18
OMIC

Singular Genomics

$4.44 /

-0.21 (-4.52%)

Reports Cash, cash…

Reports Cash, cash equivalents and short-term investments, excluding restricted cash, as of June 30, totaled $287.5M. "Shipment of the first G4 production system represents another major milestone for Singular Genomics. The G4 offers an unmatched combination of power, speed, accuracy and flexibility. We are excited this unique value proposition is resonating with customers," said Drew Spaventa, Chairman and Chief Executive Officer. "Over the second half of the year, the team will remain highly focused on executing our commercial strategy under new leadership, ramping manufacturing and establishing the right foundation to scale the business."

ShowHide Related Items >><<
OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/07/22 BofA
Singular Genomics upgraded to Buy from Neutral at BofA
01/06/22 UBS
Singular Genomics price target lowered to $25 from $32 at UBS
10/14/21 Cowen
Singular Genomics coverage transferred at Cowen
OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

OMIC Singular Genomics
$4.44 /

-0.21 (-4.52%)

Recommendations
10x Genomics price target raised to $55 from $50 at Cowen » 07:35
08/09/22
08/09
07:35
08/09/22
07:35
TXG

10x Genomics

$43.45 /

+0.83 (+1.95%)

Cowen analyst Dan Brennan…

Cowen analyst Dan Brennan raised the firm's price target on 10x Genomics to $55 from $50 and keeps an Outperform rating on the shares. The analyst said preannouncing a 2Q miss the focus was on the extent of a 2022 guidance cut which looks reasonable and clarity on the issues where a recovery where visibility remains low.

ShowHide Related Items >><<
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

08/09/22 Citi
10x Genomics price target lowered to $65 from $100 at Citi
07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

Recommendations
10x Genomics price target lowered to $65 from $100 at Citi » 06:35
08/09/22
08/09
06:35
08/09/22
06:35
TXG

10x Genomics

$43.45 /

+0.83 (+1.95%)

Citi analyst Patrick…

Citi analyst Patrick Donnelly lowered the firm's price target on 10x Genomics to $65 from $100 and keeps a Buy rating on the shares post the Q2 results. Particular focus was the lowered fiscal 2022 revenue guidance, which management attributed to China COVID lockdowns, currency headwinds, and the post-pandemic growth ramp tracking below expectations, Donnelly tells investors in a research note. The analyst believes the guidance reduction was broadly expected, but views the updated guidance cut of $100M as worse than anticipated.

ShowHide Related Items >><<
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

07/25/22 Canaccord
Canaccord starts 10x Genomics at Buy, sees multiple avenues for long-term growth
07/25/22 Canaccord
10x Genomics initiated with a Buy at Canaccord
07/15/22 Morgan Stanley
10x Genomics reset a 'clearing event,' says Morgan Stanley
07/15/22 BofA
BofA sees 'no quick fix' for 10x Genomics, downgrades to Underperform
TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

TXG 10x Genomics
$43.45 /

+0.83 (+1.95%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.